Responsibility. It is understood and agreed that [[Organization A:Organization]] is solely responsible for searching for, identifying, evaluating or obtaining access to, Patent Rights Controlled by Third Parties (expressly excluding the [[Agenus:Organization]] IP) that may be infringed by the Development, Manufacture or Commercialization of the Licensed Product in accordance with this Agreement. [[Agenus:Organization]] shall have no responsibility or liability to [[Organization A:Organization]] with respect to such Third Party Patent Rights. In the event that either Party receives any notice of potential infringement of any Third Party Patent Rights as a result of, or otherwise impacting, the Exploitation of the Licensed Product, it shall promptly notify the other Party.

Responsibility. Each Recipient shall be responsible for any breach of the obligations of this Section 12.1 by any Person to whom such Recipient or its Affiliate disclosed the Disclosing Party’s Confidential Information.

Responsibility. On a Collaboration Target-by-Collaboration Target basis, following the License Effective Date with respect to the Licensed Development Candidate(s) Directed to such Collaboration Target, BMS shall have the sole right and responsibility, at its own cost and expense, to # prepare, file and maintain INDs, Drug Approval Applications, and other Marketing Approvals and regulatory filings related to such Licensed Development Candidate(s) and Licensed Products, each in its own name, and # communicate with Regulatory Authorities with respect to Licensed Products Directed to such Collaboration Target, either by itself or with or through one or more Affiliates or Third Parties.

Responsibility. It is understood and agreed that searching for, identification and evaluation of Third Party Patents that may apply to any Excluded Technology or Sequence IP, including Patents that apply Program-Benefited Antibodies and Products based on sequence, Target, methods of treatment using any Program-Benefited Antibodies, or the like is the responsibility of [[Alector:Organization]], and that [[Adimab:Organization]] will have no responsibility for the foregoing nor liability if any such Third-Party Patents exist; provided, however, that the foregoing shall not diminish or otherwise mitigate [[Adimab:Organization]]’s obligations under [Section 7.2(e)] (No Incorporation of Proprietary Technology).

Responsibility. Except as otherwise provided in this Agreement, CANbridge will be ​. LogicBio will, and will cause its Affiliates to, ​.

Responsibility. Apellis shall use Commercially Reasonable Efforts to oversee the activities of its Vendors. For clarity, Apellis will remain primarily responsible for all its obligations under this Agreement, notwithstanding any delegation to an Affiliate or a CRO and/or contracting with a Vendor, as if Apellis had not so delegated and/or contracted with respect to such responsibilities.

Responsibility. With the exception of the [[Unknown Identifier]] Phase 1 Clinical Trial and any other Phase 1 Clinical Trial relating to [[Unknown Identifier]] mutually agreed between the Parties after the Effective Date, and subject to the terms and conditions of this Agreement, Bayer shall be solely responsible for the Development of the Licensed Cell Therapeutics and / or Licensed Products in the Field in the Territory, at Bayer’s sole discretion (subject to [Section 4.4]) and Bayer’s sole expense, including for the avoidance of doubt:

Responsibility. Subject to the terms and conditions of this Agreement, Bayer shall be solely responsible for the Commercialization of the Licensed Product in the Field in the Territory at Bayer’s sole expense (except as set forth elsewhere in this Agreement), including, for the avoidance of doubt, the planning and implementation, distribution, booking of sales, pricing and reimbursement, in all cases, whether performed by or on behalf of Bayer or any other Bayer Party or Third Party appointed by Bayer.

Responsibility. It is understood and agreed that Betta is solely responsible for searching for, identifying, evaluating or obtaining access to, Patent Rights Controlled by Third Parties (expressly excluding the Licensed IP) that may be infringed by Betta’s Development, Manufacture or Commercialization of the Licensed Antibodies or Licensed Products in the Field in the Territory in accordance with this Agreement. [[Agenus:Organization]] will have no responsibility or liability to Betta with respect to such Third Party Patent Rights. In the event that either Party receives any notice of potential infringement of any Third Party Patent Rights as a result of, or otherwise impacting, the Exploitation of the Licensed Product, it will promptly notify the other Party.

Responsibility. For each of the [[Unknown Identifier]] and ​ Programs, following the completion of the applicable [[Unknown Identifier]] Technology Transfer or ​ Technology Transfer, # Acadia shall be solely responsible, at its sole expense, for all regulatory activities necessary to obtain and maintain Regulatory Approval of the applicable Licensed Products in the Field in the Territory, and # Acadia will own all Regulatory Materials for such Licensed Products in the Field in the Territory, including all Regulatory Approvals, and will be responsible for the payment of fees and all other associated regulatory costs for such Licensed Products in the Field in the Territory.